baudax
bio
present
oppenheimer
fall
healthcare
life
sciences
medtech
summit
malvern
globe
newswire
baudax
bio
nasdaq
bxrx
pharmaceutical
company
focused
therapeutics
acute
care
settings
today
announced
gerri
henwood
company
president
chief
executive
officer
present
oppenheimer
fall
healthcare
life
sciences
medtech
summit
tuesday
september
et
live
webcast
presentation
available
presentations
page
within
investors
section
baudax
bio
website
https
replay
available
baudax
bio
website
period
days
following
event
baudax
bio
baudax
bio
pharmaceutical
company
focused
therapeutics
acute
care
settings
launch
company
first
commercial
product
began
june
baudax
new
drug
application
anjeso
approved
fda
february
management
management
moderate
severe
pain
alone
combination
analgesics
anjeso
daily
iv
nsaid
preferential
activity
successfully
completed
three
phase
iii
clinical
trials
including
two
pivotal
efficacy
trials
large
phase
iii
safety
trial
studies
management
moderate
severe
pain
iv
meloxicam
potential
overcome
many
issues
associated
commonly
prescribed
opioid
therapeutics
including
respiratory
depression
constipation
excessive
nausea
vomiting
well
addictive
potential
maintaining
meaningful
analgesic
effects
relief
pain
information
please
visit
contact
investor
relations
contact
argot
partners
sam
martin
claudia
styslinger
sam
claudia
baudax
bio
ryan
lake
rlake
media
contact
argot
partners
david
rosen
